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Abstract: Exfoliation syndrome (XFS) is an age-related disorder of the extracellular matrix that leads the production of 
abnormal fibrillar material that leads to elevated intraocular pressure and a relatively severe glaucoma. Exfoliation 
material is deposited in numerous ocular tissues and extraocular organs. XFS is associated with ocular ischemia, 
cerebrovascular disease, neurodegenerative disease and cardiovascular disease. Current modalities of treatment include 
intraocular pressure lowering with topical antihypertensives, laser trabeculoplasty and filtration surgery. The disease 
paradigm for XFS should be expanded to include directed therapy designed specifically to target the underlying disease 
process. Potential targets include preventing the formation or promoting the depolymerization of exfoliation material. 
Novel therapies targeting trabecular meshwork may prove particularly useful in the care of exfoliative glaucoma. The 
systemic and ocular associations of XFS underscore the need for a comprehensive search for neuroprotective agents in its 
treatment. 
1. PATHOGENESIS AND PRESENTATION OF 
EXFOLIATION SYNDROME 
Epidemiology and Clinical Presentation 
  Exfoliation syndrome (XFS) is an age-related disease of 
the extracellular matrix characterized by the production and 
deposition of a fibrillar extracellular material in numerous 
ocular tissues. It is now recognized as the most common 
identifiable cause of open-angle glaucoma, affecting an 
estimated 60 to 70 million people worldwide [1, 2]. Its 
reported prevalence rates vary extensively due to true 
population variations as well as the clinical criteria used and 
the ability of the examiner to detect the clinical signs of the 
disease. 
  The diagnosis of XFS is confirmed by the presence of 
white exfoliation material (XFM) at the pupillary border or 
on the anterior lens capsule in a characteristic distribution. A 
central disc is separated from a granular peripheral zone by 
an intermediate clear zone denuded of XFM by friction 
between the iris and anterior lens capsule during pupillary 
movement. The material on the anterior lens capsule causes 
rupture of iris pigment epithelial cells leading to pigment 
dispersion, trabecular meshwork hyperpigmentation, iris 
transillumination defects at the pupillary margin and loss of 
the pupillary ruff. Pigment dispersion after dilation can lead 
to marked IOP rise and may be one of the earliest 
manifestations of the disease. 
  Patients with XFS are twice as likely to convert from 
ocular hypertension to detectable glaucoma [3]. Exfoliative 
glaucoma (XFG) is more severe than primary open angle 
glaucoma (POAG). There is greater diurnal intraocular   
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pressure (IOP) fluctuation, greater visual field loss and optic 
nerve head damage at presentation, poorer response to 
medications, faster visual field progression and increased 
need for surgical intervention. At any given IOP, eyes with 
XFS are at significantly greater risk for glaucomatous 
damage, suggesting that pressure-independent factors play a 
significant role in visual field loss in these patients. 
  The prevalence of XFS increases with age in all affected 
populations. Approximately two-thirds of patients have 
unilateral disease on clinical examination; however, XFS is 
often detectable in the contralateral eye with conjunctival 
biopsy [4]. This finding supports the hypothesis that the 
development of XFS is similar to uveitis in that an 
underlying predisposition plus an environmental or 
immunologic trigger leads to disease manifestation. 
Pathogenesis of XFS 
  The pathogenesis of XFS is defined by the accumulation 
of an abnormal fibrillar material biochemically related to the 
composition of the extracellular matrix that results either 
from excessive production and/or insufficient breakdown. 
The product has a unique structure as seen by electron 
microscopy [5]. Streeten et al. first hypothesized that XFS is 
an elastosis based on similarities of XFM and zonular fibers 
[6]. These characteristic fibrils, composed of microfibrillar 
subunits surrounded by an amorphous matrix, contain 
epitopes of elastic fibers such as fibrillin-1, elastin, 
tropoelastin, amyloid P and microfibril-associated 
glycoprotein, vitronectin and the cross-linking enzyme lysyl-
oxidase [7, 8]. 
  Two common single nucleotide polymorphisms (SNPs) 
in the coding region of the lysyl-oxidase-like 1 (LOXL1) 
gene on chromosome 15 have been identified and account 
for virtually all cases of XFS in several populations [9-12]. 
While the SNPs confer susceptibility to XFS, not all people 
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  LOXL1 is a member of the lysyl oxidase enzyme family 
responsible for formation, stabilization and remodeling of 
elastic fibers. They are important for cross-linking of elastin, 
for providing a scaffold that ensures spatially defined 
deposition of elastin and for regulating the production of 
elastin [13, 14]. The currently proposed pathogenesis of XFS 
is a stress-related, excessive production by elastogenic cells 
of elastic microfibrils that aggregate into a typical 
configuration via an enzymatic cross-linking process [15]. 
There is evidence that derangement of the balance of matrix 
metalloproteinases and their tissue inhibitors, increased 
oxidative stress and an impaired stress response contribute to 
impaired degradation and accumulation of fibers [16-19]. 
These fibers impair trabecular meshwork outflow resulting 
in an increased rise of IOP. 
Ocular and Systemic Associations 
  XFS is associated with both chronic open-angle 
glaucoma and angle closure. The zonules and ciliary body 
are often diffusely coated with XFM and zonules are often 
frayed and broken. Zonular fragility and poor pupillary 
dilation contribute to an increased incidence of serious 
complications during cataract extraction, including zonular 
dehiscence and vitreous loss. Phacodonesis and even 
subluxation of the lens or intraocular lens is common. 
  It appears that XFS is etiologically related to cataract 
formation itself. Decreased aqueous humor ascorbic acid 
concentrations in XFS [20], increased malondialdehyde 
concentrations [21] and increased 8-iso-prostaglandinF2a [22] 
suggest that free radicals and oxidative damage play a role in 
the disease process. There is also breakdown of the blood-
aqueous barrier with resultant increased protein 
concentrations in the anterior chamber. 
  Ocular ischemia is clearly correlated with XFS. An 
increased frequency of retinal vein occlusion has been noted 
in XFS [23-25] and iris hypoperfusion can be detected 
angiographically and histopathologically [26, 27]. Patchy iris 
neovascularization can be seen when capillary dropout is 
extensive [7, 15]. Deposits of XFM can be found in the walls 
of vortex veins and central retinal veins. Not surprisingly, 
cardiovascular and cerebrovascular disorders are emerging 
as systemic associations of XFS. XFM has been found 
electron microscopically in the heart, liver, lungs, kidney and 
meninges in patients with XFS [28, 29]. Ocular, retrobulbar, 
cerebral and carotid blood flow are reduced [30-34]. XFS is 
a risk factor for cardiovascular disease [35] and several 
reports have linked XFS with Alzheimer’s disease, hearing 
loss and transient ischemic attacks [36-39]. The pathologic 
connection between XFM and the functional deficits seen is 
currently unclear. 
2. DIRECTED THERAPY FOR XFS 
  As the term implies, directed therapy aims to specifically 
address and interfere with the underlying disease pathogenesis. 
Ophthalmologists have begun to recognize the inadequacy of 
therapy limited solely to IOP reduction, particularly with the 
significant potential morbidities associated with XFS. The 
widespread systemic and ocular manifestations of XFS 
underscore the need for a broad and comprehensive treatment 
paradigm. It is essential that future investigations focus on 
disease-specific therapeutic modalities. 
Directed Ocular Antihypertensive Therapy 
    The management of XFS currently hinges on ocular 
antihypertensive therapy and initially can be achieved with 
topical therapy in many cases. Prostaglandin analogues such 
as latanoprost and travoprost reduce IOP at each time point 
in the 24-hour diurnal curve as compared to untreated IOP, 
with travoprost conferring a slightly higher level of reduction 
[40]. Latanoprost reduced IOP and narrowed the range of 
diurnal fluctuation in comparison to timolol in XFS [41]. 
  Pilocarpine has multiple beneficial actions in eyes with 
XFS. Not only does it lower IOP, but by increasing aqueous 
outflow, it should enable the trabecular meshwork to clear 
more rapidly, and by limiting pupillary movement, should 
slow disease progression. Theoretically, miotics should be 
the first line of treatment. Prostaglandin analogues are 
complementary in increasing uveoscleral outflow facility. By 
decreasing outflow, aqueous suppressants may cause 
longterm worsening of trabecular function that may be 
particularly detrimental in XFS [42].
 
  Unfortunately, pilocarpine is underutilized in the 
treatment of glaucoma due to the possibility of decreased 
vision or the misconception that it must be used q.i.d. It is 
our experience that pilocarpine 2% q.h.s. can provide 
significant limitation of pupillary movement without the 
inconvenience of q.i.d. dosing and dimming of vision. 
Pilocarpine can also blunt an early morning IOP spike [43]. 
  Argon laser trabeculoplasty is particularly effective in 
XFS [44]. Primary ALT can delay the need for topical 
therapy in some patients, although there is a general decrease 
in efficacy over time, with 35-55% remaining medication 
free at 3-5 years [45]. A minority of patients will experience 
a sudden and dramatic rise in IOP within two years 
following treatment, presumably due to continued pigment 
liberation overwhelming the meshwork. Pilocarpine 2% 
q.h.s. may provide protection from this. Limited data on 
selective laser trabeculoplasty (SLT) suggests that success 
may be comparable, although prospective studies are 
necessary to confirm this and also to compare results with 
argon laser trabeculoplasty [46]. Marked IOP elevations 
associated with pigment release in patients with heavily 
pigmented trabecular meshworks necessitating filtration 
surgery may occur after SLT [47]. Trabeculectomy with 
antifibrotic therapy leads to comparable IOP reduction in 
XFS and OAG, and offers greater 24-hour IOP control than 
medical therapy alone [48]. 
  The investigation of surgical therapy directed at 
trabecular dysfunction is particularly sensible for XFS. 
Trabeculotomy has been reported as successful in XFS 
although additional trials are required [49-51]. Goniotomy is 
also successful (Kim JH, Sbeity Z, Ritch R: Long-term 
results of goniotomy and cataract surgery for exfoliative 
glaucoma. Southeast Asian Glaucoma Interest Group, Seoul, 
Republic of Korea, Sept. 25, 2008.) Jacobi and Krieglstein 
[52] described a procedure in which trabecular aspiration 
improves outflow facility. 
Novel Therapies Targeting Trabecular Meshwork 
  Drugs that alter the structure of the trabecular meshwork 
may be particularly effective in XFS. Latrunculin B is 
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bind to free actin in trabecular cells leading, to temporary 
disintegration of the existing actin cytoskeletin thereby 
increasing aqueous outflow [53, 54]. Unlike previous 
compounds with similar mechanisms of action such as 
sodium-EDTA and cytochalasin B [55, 56], Latrunculin has 
no known adverse effects on retinal and corneal function 
[57-59]. Ideally, latrunculin would be effective as a depot 
medication with once a week or once a month dosing. 
Treatment Directed at XFM 
  Future therapy of XFS should be directed at preventing 
formation of XFM or depolymerizing existing XFM. An 
intriguing line of research is an investigation of the factors 
that protect the contralateral eye from developing XFS. If the 
development of the disease in the second eye is actively 
suppressed, as by an immune mechanism, then elucidation of 
this could lead to a novel treatment. The systemic 
ramifications of XFS and the morbidity associated with these 
diseases highlight the need for a therapy that prevents 
aggregation of XFM microfibrils disaggregating the 
microfibrils. 
  Homocysteine is an amino acid, elevations of which 
result from a disturbance of methionine metabolism. 
Hyperhomocysteinemia is a widely recognized 
cardiovascular risk factor and is reversible with dietary 
supplementation with folic acid, pyridoxine (vitamin B6) and 
cyanocobalamine (vitamin B12) [60, 61]. Hyperhomocysteinemia 
is associated with disruption of the elastic fibers of the 
extracellular matrix leading to vascular disease [62]. 
Elevated homocysteine levels are present in blood, aqueous 
and tears of patients with XFS, and there are decreased 
serum levels of cyanocobalamin, pyridoxine and folic acid 
[63-66]. The concept of a relationship between 
hyperhomocysteinemia is supported by the propensity for 
cardiovascular and cerebrovascular disease in patients with 
XFS. By the same virtue, it is possible that treatment of 
hyperhomocysteinemia could be beneficial in XFS as it is in 
cardiovascular disease. 
  Folic acid deficiency leads to altered expression of genes 
involved in cell signaling, the cytoskeleton and the 
extracellular matrix [67]. Actin disrupting agents, such as 
latrunculin B, reversibly increase the proportion of receptors 
on the cell surface and increase [68] the rate of 5-
methyltetrahydrofolate delivery [69]. Pyridoxine is an 
essential micronutrient involved in a variety of critical 
metabolic reactions including carbohydrate metabolism, 
sphingolipid biosynthesis and degradation, amino acid 
metabolism (including that of homocysteine), and 
neurotransmitter metabolism [70]. Therefore, deficiency of 
this essential micronutrient in humans leads to a variety of 
adverse conditions and to disturbances in normal cellular 
metabolism. Pyridoxine also plays a role in the integrity of 
the extracellular matrix [71]. Cyanocobalamin is important 
for the normal functioning of the brain and nervous system 
and for the formation of blood. It is normally involved in the 
metabolism of every cell of the body, especially affecting the 
DNA synthesis and regulation but also fatty acid synthesis 
and energy production. 
  The discovery of the role of LOXL1 polymorphisms in 
XFS draws attention towards lysyl oxidase and its role in 
XFM production. Lysyl oxidase is inhibited by 
homocysteine in vascular endothelia and is also regulated by 
transforming growth factor-ß1 (TGF- ß1) [72, 14]. Levels of 
TGF-ß1 are significantly increased in the aqueous humor of 
XFS and TGF- ß1 may be responsible for overproduction of 
extracellular matrix in XFS [73]. Further information on the 
biochemical pathway of the production of XFM is critical if 
we hope to modify the treatment of XFS significantly. 
Treatment Targeting Non-pressure Dependent 
Mechanisms 
  Patients with XFS have an increased likelihood to have 
coexisting cerebrovascular and cardiovascular disease, and 
systemic agents that provide neuroprotection and 
vasoprotection may prove to be an important therapeutic 
tactic in the treatment of XFS. Pharmacologic treatment of 
non-IOP dependent mechanisms in glaucoma has 
traditionally been limited to calcium channel blockers that 
are widely used in treatment of hypertension, coronary artery 
disease, migraines and Raynaud’s disease. The effect of 
calcium channel blockers on visual field progression and 
ocular blood flow is disputed [74-76]. 
  Gingko biloba extract (GBE) has been used in Chinese 
medicine since 3000 BC for the treatment of aging, 
dementia, tinnitus, bronchoconstriction and sexual 
dysfunction with minimal side effects. It improves 
peripheral, cerebral and ocular blood flow, prevents platelet 
aggregation and protects against free radical damage [77, 
78]. Neurons in tissue culture are protected from toxicity-
induced apoptosis with GBE, and there is mixed evidence 
that GBE improves function in patients with Alzheimer’s 
disease and vascular dementia [79, 80]. Further elucidation 
by prospective trials of GBE in glaucoma is warranted. 
  Curcumin is an anti-oxidant extracted from the plant 
Curcuma longa and is a component of the commonly used 
Indian spice turmeric. Curcumin has antioxidant, anti-
inflammatory, anti-angiogenic and anti-neoplastic activity 
via  the inhibition of numerous mediators of inflammation 
[81-85]. Clinical trials for the treatment of gastrointestinal 
and other neoplasms as well as Alzheimer’s disease are 
under way. Common therapeutic doses cause only mild 
gastrointestinal discomfort in a minority of patients. 
  Resveratrol is a compound found in the skin of red 
grapes. It is an effective antioxidant and protects against 
degeneration of neurons in ischemia. It is hypothesized that 
resveratrol is responsible for the “French paradox”, the 
observation that the French have a lower incidence of heart 
disease despite a high fat diet due to the consumption of red 
wine. It is an effective antioxidant and prevents neuron 
degeneration [84, 85]. 
3. CONCLUSION 
  XFS is a systemic disorder with components of low-
grade inflammation and oxidative damage leading to 
accumulation of XFM. The ocular morbidity associated with 
XFS far exceeds that of open-angle glaucoma, and a host of 
systemic diseases with considerable morbidity and mortality 
are associated with XFS. Further elucidation of the genetics 
and pathophysiology of XFS is crucial to our ability to treat 
this disease effectively. There is a role for non-IOP lowering 
treatment modalities in XFS as there is significant evidence 
of generalized ischemia and neurodegeneration. With this Directed Therapy for Exfoliation Syndrome  The Open Ophthalmology Journal, 2009, Volume 3    73 
directed investigation, there is hope that XFS will be both a 
preventable and curable disease. 
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